Impact of CAR T-cell therapy in Earlier Lines of MM
A panel of experts examines the impact and potential of CAR T-cell therapy in earlier treatment lines for multiple myeloma, evaluating its efficacy, safety.
EP: 1.Transplant Eligible Multiple Myeloma: Current Standard of Care and Treatment Landscape
EP: 2.Updates from EHA 2024: Review of PERSEUS and IsKIA
EP: 3.Clinical Implications of Updated Data from EHA 2024
EP: 4.Updated Data from EHA 2024: Transplant Ineligible NDMM
EP: 5.Impact of CAR T-cell therapy in Earlier Lines of MM
EP: 6.CAR T-cell therapy in MM: Updated Data and the Future
Video content above is prompted by the following:
- Let’s talk about the use of CAR T-cell therapy in early R/R MM. Please share your thoughts on the following data:
- CARTITUDE-4
- KarMMa-3
- How does the CAR T-cell fit into 2nd line treatment in your practice and in which patients do you use CAR T-cell in?
- How does CAR T-cell therapy in the 2nd line affect your approach to front-line therapy for MM?
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
